日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis

晚期上皮性卵巢癌一线化疗后PARP抑制剂维持治疗:系统评价和荟萃分析

Petousis, Stamatios; Kahramanoglu, Ilker; Appenzeller-Herzog, Christian; Angeles, Martina A; Margioula-Siarkou, Chrysoula; Kacperczyk-Bartnik, Joanna; Bilir, Esra; Chatzakis, Christos; Caruso, Giuseppe; Bizzarri, Nicolò; Dinas, Konstantinos; Bowtell, David D L; Garsed, Dale W; Ray-Coquard, Isabelle; Ledermann, Jonathan A; Friedlander, Michael; Sotiriadis, Alexandros; Heinzelmann-Schwarz, Viola; Zwimpfer, Tibor A

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Rucaparib用于铂敏感复发性卵巢癌维持治疗:3期随机、安慰剂对照ARIEL3试验的最终结果

Ledermann, Jonathan A; Oza, Amit M; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana; Dean, Andrew; Colombo, Nicoletta; Weberpals, Johanne I; Clamp, Andrew R; Scambia, Giovanni; Leary, Alexandra; Holloway, Robert W; Gancedo, Margarita Amenedo; Fong, Peter C; Goh, Jeffrey C; O'Malley, David M; Armstrong, Deborah K; Banerjee, Susana; García-Donas, Jesús; Swisher, Elizabeth M; Lebreton, Coriolan; Konecny, Gottfried E; McNeish, Iain A; Scott, Clare L; Maloney, Lara; Goble, Sandra; Lin, Kevin K; Coleman, Robert L

Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer

PARP抑制剂在卵巢癌治疗中的应用争议及临床未知因素

Mukherjee, Uma A; Miller, Rowan E; Ledermann, Jonathan A

Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London

伦敦一项回顾性观察研究:卵巢癌临床试验参与中的种族和社会经济差异

El-Shakankery, Karim H; Kefas, Joanna; Palmer, Kieran; Houston, Andrew; Mukherjee, Uma; Gao, Kangbo; Tan, Weiteen; Crusz, Shanthini M; Flynn, Michael J; Ledermann, Jonathan A; Lockley, Michelle; McCormack, Mary; MacDonald, Nicola; Nicum, Shibani; Devlin, Michael John; Miller, Rowan E

Self-supervised deep learning for highly efficient spatial immunophenotyping.

用于高效空间免疫表型分析的自监督深度学习

Zhang Hanyun, AbdulJabbar Khalid, Grunewald Tami, Akarca Ayse U, Hagos Yeman, Sobhani Faranak, Lecat Catherine S Y, Patel Dominic, Lee Lydia, Rodriguez-Justo Manuel, Yong Kwee, Ledermann Jonathan A, Le Quesne John, Hwang E Shelley, Marafioti Teresa, Yuan Yinyin

Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both

接受阿维鲁单抗、聚乙二醇化脂质体阿霉素或两者联合治疗的卵巢癌患者的左心室射血分数

Bonaca, Marc P; Moslehi, Javid J; Ledermann, Jonathan A; Michelon, Elisabete; Wei, Caimiao; Moran, Michael; Monk, Bradley J; Pujade-Lauraine, Eric

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

一线治疗上皮性卵巢癌、输卵管癌或原发性腹膜癌的每周高剂量化疗(ICON8):一项开放标签、随机、对照的3期试验的总生存期结果

Clamp, Andrew R; James, Elizabeth C; McNeish, Iain A; Dean, Andrew; Kim, Jae-Won; O'Donnell, Dearbhaile M; Gallardo-Rincon, Dolores; Blagden, Sarah; Brenton, James; Perren, Tim J; Sundar, Sudha; Lord, Rosemary; Dark, Graham; Hall, Marcia; Banerjee, Susana; Glasspool, Rosalind M; Hanna, C Louise; Williams, Sarah; Scatchard, Kate M; Nam, Helena; Essapen, Sharadah; Parkinson, Christine; McAvan, Lucy; Swart, Ann Marie; Popoola, Babasola; Schiavone, Francesca; Badrock, Jonathan; Fananapazir, Fuad; Cook, Adrian D; Parmar, Mahesh; Kaplan, Richard; Ledermann, Jonathan A

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer

卵巢癌复发:PARP抑制剂和其他介入治疗是否会改变铂类耐药的定义?铂类耐药卵巢癌治疗格局的演变

Flynn, Michael J; Ledermann, Jonathan A

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

复发性卵巢癌化疗的症状负担和生活质量:妇科癌症协作组-症状获益研究

Lee, Yeh Chen; King, Madeleine T; O'Connell, Rachel L; Lanceley, Anne; Joly, Florence; Hilpert, Felix; Davis, Alison; Roncolato, Felicia T; Okamoto, Aikou; Bryce, Jane; Donnellan, Paul; Oza, Amit M; Avall-Lundqvist, Elisabeth; Berek, Jonathan S; Ledermann, Jonathan A; Berton, Dominique; Sehouli, Jalid; Feeney, Amanda; Kaminsky, Marie-Christine; Diamante, Katrina; Stockler, Martin R; Friedlander, Michael L

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

ARIEL3 患者接受 rucaparib 维持治疗后获益显著,这些患者患有高级别卵巢癌,其临床和分子特征如下:

O'Malley, David M; Oza, Amit M; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana; Dean, Andrew; Colombo, Nicoletta; Weberpals, Johanne I; Clamp, Andrew R; Scambia, Giovanni; Leary, Alexandra; Holloway, Robert W; Gancedo, Margarita Amenedo; Fong, Peter C; Goh, Jeffrey C; Swisher, Elizabeth M; Maloney, Lara; Goble, Sandra; Lin, Kevin K; Kwan, Tanya; Ledermann, Jonathan A; Coleman, Robert L